• Je něco špatně v tomto záznamu ?

Radiogenomic markers enable risk stratification and inference of mutational pathway states in head and neck cancer

CP. Spielvogel, S. Stoiber, L. Papp, D. Krajnc, M. Grahovac, E. Gurnhofer, K. Trachtova, V. Bystry, A. Leisser, B. Jank, J. Schnoell, L. Kadletz, G. Heiduschka, T. Beyer, M. Hacker, L. Kenner, AR. Haug

. 2023 ; 50 (2) : 546-558. [pub] 20220926

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, komentáře

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004810

PURPOSE: Head and neck squamous cell carcinomas (HNSCCs) are a molecularly, histologically, and clinically heterogeneous set of tumors originating from the mucosal epithelium of the oral cavity, pharynx, and larynx. This heterogeneous nature of HNSCC is one of the main contributing factors to the lack of prognostic markers for personalized treatment. The aim of this study was to develop and identify multi-omics markers capable of improved risk stratification in this highly heterogeneous patient population. METHODS: In this retrospective study, we approached this issue by establishing radiogenomics markers to identify high-risk individuals in a cohort of 127 HNSCC patients. Hybrid in vivo imaging and whole-exome sequencing were employed to identify quantitative imaging markers as well as genetic markers on pathway-level prognostic in HNSCC. We investigated the deductibility of the prognostic genetic markers using anatomical and metabolic imaging using positron emission tomography combined with computed tomography. Moreover, we used statistical and machine learning modeling to investigate whether a multi-omics approach can be used to derive prognostic markers for HNSCC. RESULTS: Radiogenomic analysis revealed a significant influence of genetic pathway alterations on imaging markers. A highly prognostic radiogenomic marker based on cellular senescence was identified. Furthermore, the radiogenomic biomarkers designed in this study vastly outperformed the prognostic value of markers derived from genetics and imaging alone. CONCLUSION: Using the identified markers, a clinically meaningful stratification of patients is possible, guiding the identification of high-risk patients and potentially aiding in the development of effective targeted therapies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004810
003      
CZ-PrNML
005      
20230425171731.0
007      
ta
008      
230418s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00259-022-05973-9 $2 doi
035    __
$a (PubMed)36161512
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Spielvogel, Clemens P $u Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
245    10
$a Radiogenomic markers enable risk stratification and inference of mutational pathway states in head and neck cancer / $c CP. Spielvogel, S. Stoiber, L. Papp, D. Krajnc, M. Grahovac, E. Gurnhofer, K. Trachtova, V. Bystry, A. Leisser, B. Jank, J. Schnoell, L. Kadletz, G. Heiduschka, T. Beyer, M. Hacker, L. Kenner, AR. Haug
520    9_
$a PURPOSE: Head and neck squamous cell carcinomas (HNSCCs) are a molecularly, histologically, and clinically heterogeneous set of tumors originating from the mucosal epithelium of the oral cavity, pharynx, and larynx. This heterogeneous nature of HNSCC is one of the main contributing factors to the lack of prognostic markers for personalized treatment. The aim of this study was to develop and identify multi-omics markers capable of improved risk stratification in this highly heterogeneous patient population. METHODS: In this retrospective study, we approached this issue by establishing radiogenomics markers to identify high-risk individuals in a cohort of 127 HNSCC patients. Hybrid in vivo imaging and whole-exome sequencing were employed to identify quantitative imaging markers as well as genetic markers on pathway-level prognostic in HNSCC. We investigated the deductibility of the prognostic genetic markers using anatomical and metabolic imaging using positron emission tomography combined with computed tomography. Moreover, we used statistical and machine learning modeling to investigate whether a multi-omics approach can be used to derive prognostic markers for HNSCC. RESULTS: Radiogenomic analysis revealed a significant influence of genetic pathway alterations on imaging markers. A highly prognostic radiogenomic marker based on cellular senescence was identified. Furthermore, the radiogenomic biomarkers designed in this study vastly outperformed the prognostic value of markers derived from genetics and imaging alone. CONCLUSION: Using the identified markers, a clinically meaningful stratification of patients is possible, guiding the identification of high-risk patients and potentially aiding in the development of effective targeted therapies.
650    _2
$a lidé $7 D006801
650    _2
$a dlaždicobuněčné karcinomy hlavy a krku $x diagnostické zobrazování $x genetika $7 D000077195
650    12
$a spinocelulární karcinom $x patologie $7 D002294
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a genetické markery $7 D005819
650    12
$a nádory hlavy a krku $x diagnostické zobrazování $x genetika $7 D006258
650    _2
$a prognóza $7 D011379
650    _2
$a hodnocení rizik $7 D018570
655    _2
$a časopisecké články $7 D016428
655    _2
$a komentáře $7 D016420
700    1_
$a Stoiber, Stefan $u Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria $u Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Papp, Laszlo $u Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
700    1_
$a Krajnc, Denis $u Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
700    1_
$a Grahovac, Marko $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
700    1_
$a Gurnhofer, Elisabeth $u Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Trachtova, Karolina $u Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria $u Centre for Molecular Medicine, Central European Institute of Technology, Brno, Czech Republic
700    1_
$a Bystry, Vojtech $u Centre for Molecular Medicine, Central European Institute of Technology, Brno, Czech Republic
700    1_
$a Leisser, Asha $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
700    1_
$a Jank, Bernhard $u Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria
700    1_
$a Schnoell, Julia $u Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria
700    1_
$a Kadletz, Lorenz $u Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria
700    1_
$a Heiduschka, Gregor $u Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria
700    1_
$a Beyer, Thomas $u Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
700    1_
$a Hacker, Marcus $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
700    1_
$a Kenner, Lukas $u Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria. lukas.kenner@meduniwien.ac.at $u Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at $1 https://orcid.org/0000000321841338
700    1_
$a Haug, Alexander R $u Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
773    0_
$w MED00007222 $t European journal of nuclear medicine and molecular imaging $x 1619-7089 $g Roč. 50, č. 2 (2023), s. 546-558
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36161512 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171728 $b ABA008
999    __
$a ok $b bmc $g 1925102 $s 1191019
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 50 $c 2 $d 546-558 $e 20220926 $i 1619-7089 $m European journal of nuclear medicine and molecular imaging $n Eur J Nucl Med Mol Imaging $x MED00007222
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace